000			03757nam a22005775i 4500
001			978-3-0346-0094-1
003			DE-He213
005			20140220083738.0
007			cr nn 008mamaa
008			110105s2011 sz | s |||| 0|eng d
020			_a9783034600941 _9978-3-0346-0094-1
024	7		_a10.1007/978-3-0346-0094-1 _2doi
050		4	_aRM1-950
072		7	_aMMG _2bicssc
072		7	_aMED071000 _2bisacsh
082	0	4	_a615 _223
100	1		_aSibilia, Maria. _eeditor.
245	1	0	_aDrugs for HER-2-positive Breast Cancer _h[electronic resource] / _cedited by Maria Sibilia, Christoph C. Zielinski, Rupert Bartsch, Thomas W. Grunt.
264		1	_aBasel : _bSpringer Basel, _c2011.
300			_aX, 110 p. _bonline resource.
336			_atext _btxt _2rdacontent
337			_acomputer _bc _2rdamedia
338			_aonline resource _bcr _2rdacarrier
347			_atext file _bPDF _2rda
490	1		_aMilestones in Drug Therapy
505	0		_aDrugs for HER-2-positive Breast Cancer: A Major Approval for Translational Cancer Research (Maria Sibilia, Christoph C. Zielinski, Rupert Bartsch, Thomas Grunt) -- The EGFR/ErbB family in breast cancer: from signaling to therapy (Wolfgang J. Köstler and Yosef Yarden) -- Trastuzumab as Adjuvant treatment for early stage HER-2 positive breast cancer (Rupert Bartsch and Guenther G. Steger) -- Trastuzumab Resistance in breast cancer (Floriana Morgillo, Michele Orditura, Teresa Troiani, Erika Martinelli, Ferdinando De Vita, Fortunato Ciardiello) -- Treatment with Trastuzumab beyond Progression (Gunter von Minckwitz and Cristina Pirvulescu) -- Pertuzumab – a HER-2 dimerisation inhibitor – for the treatment of breast and other cancers (Giulia Bianchi and Luca Gianni) -- Beyond trastuzumab: Second generation targeted therapies for HER2--positive breast cancer (Flavio F. Solca, Guenther R. Adolf, Hilary Jones, Martina M. Uttenreuther-Fischer).
520			_aGrowth factor receptors have long been known to drive malignant transformation and cancer progression. The epidermal growth factor receptor (EGFR, ErbB, HER) system is likely the best described membrane receptor tyrosine kinase family in malignant tumors. With implementation of the growth-inhibitory anti-HER-2 antibody trastuzumab (Herceptin) for the treatment of HER-2-positive advanced metastatic breast cancer, a new era has dawned in the therapy of this malignant disease. Unfortunately, trastuzumab-sensitive cancers invariably develop resistance to the antibody after some time. Recent clinical studies have revealed that these refractory tumors are still responsive to inhibition of the HER receptor family using dual HER-1/-2 inhibitors such as lapatinib (Tykerb/Tyverb). Moreover, a multiplicity of novel, improved irreversibly acting small molecular HER tyrosine kinase inhibitors are in the pipeline of many drug developing companies and are being evaluated in the clinical setting.
650		0	_aMedicine.
650		0	_aOncology.
650		0	_aImmunology.
650		0	_aMonoclonal antibodies.
650		0	_aToxicology.
650		0	_aInternal medicine.
650	1	4	_aBiomedicine.
650	2	4	_aPharmacology/Toxicology.
650	2	4	_aOncology.
650	2	4	_aCancer Research.
650	2	4	_aAntibodies.
650	2	4	_aImmunology.
650	2	4	_aInternal Medicine.
700	1		_aZielinski, Christoph C. _eeditor.
700	1		_aBartsch, Rupert. _eeditor.
700	1		_aGrunt, Thomas W. _eeditor.
710	2		_aSpringerLink (Online service)
773	0		_tSpringer eBooks
776	0	8	_iPrinted edition: _z9783034600934
830		0	_aMilestones in Drug Therapy
856	4	0	_uhttp://dx.doi.org/10.1007/978-3-0346-0094-1
912			_aZDB-2-SBL
999			_c106567 _d106567